Physician
Oklahoma Arthritis Center, P.C.
Oklahoma Arthritis Center, P.C. was paid $10.11M by Medicaid between Jan 2018 and Nov 2024, across 65 billing codes. Its largest line is J0490, Injection, belimumab, 10 mg — 35% of everything it billed.
33Billing provider infoOKLAHOMA ARTHRITIS CENTER, P.C.
EDMOND, OK 73013
EDMOND, OK 73013
33aNPI1528036019assigned 03/09/2006
33bProvider typeRheumatology Physician
28Total paid$10.11M
24GClaims125,217
24DCodes billed65
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rheumatology Physician providers in Oklahoma
Rank by total paid#1 of 8
Median peer was paid$19K
This provider vs. median544×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 642 | $13K | |
| 2019 | 1,582 | $40K | |
| 2020 | 5,296 | $155K | |
| 2021 | 15,084 | $770K | |
| 2022 | 29,863 | $2.66M | |
| 2023 | 47,347 | $5.36M | |
| 2024incomplete | 25,403 | $1.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0490 | Injection, belimumab, 10 mg | 35% | 1,238 | 914 | $3.56M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 21,542 | 21,418 | $1.88M |
| J0491 | Injection, anifrolumab-fnia, 1 mg | 12% | 290 | 278 | $1.23M |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 10% | 824 | 607 | $1.02M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.7% | 6,435 | 6,109 | $480K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 3.2% | 657 | 422 | $327K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.4% | 1,982 | 1,982 | $244K |
| 86235 | 1.9% | 1,269 | 1,267 | $195K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.3% | 2,261 | 2,249 | $133K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 1.1% | 54 | 50 | $109K |
| 80053 | Comprehensive metabolic panel | <1% | 10,479 | 10,456 | $95K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,308 | 5,948 | $86K |
53 more codes
| 99205 | Prolong outpt/office vis | <1% | 443 | $77K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,372 | $75K |
| 86140 | <1% | 13,709 | $61K | |
| 86480 | <1% | 960 | $52K | |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 30 | $42K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,963 | $33K |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 3,225 | $32K |
| 85652 | <1% | 12,372 | $29K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 801 | $21K |
| 73130 | <1% | 691 | $20K | |
| 96415 | <1% | 1,152 | $19K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,835 | $18K |
| 73560 | <1% | 690 | $18K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 684 | $17K |
| 73620 | <1% | 682 | $15K | |
| 86225 | <1% | 1,279 | $15K | |
| 86200 | <1% | 1,288 | $14K | |
| 86038 | <1% | 1,275 | $13K | |
| 73120 | <1% | 603 | $13K | |
| 80050 | General health panel | <1% | 416 | $12K |
| 72052 | <1% | 243 | $12K | |
| 86803 | <1% | 948 | $12K | |
| 73521 | <1% | 338 | $11K | |
| 86704 | <1% | 985 | $10K | |
| 86160 | <1% | 476 | $10K | |
| 73565 | <1% | 314 | $10K | |
| 82728 | <1% | 789 | $9K | |
| 86706 | <1% | 943 | $9K | |
| 87340 | <1% | 941 | $8K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,969 | $8K |
| 84481 | <1% | 476 | $7K | |
| 86431 | <1% | 1,205 | $6K | |
| 83550 | <1% | 783 | $6K | |
| 72110 | <1% | 131 | $5K | |
| 72100 | <1% | 143 | $5K | |
| 83540 | <1% | 782 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 448 | $4K |
| 84439 | <1% | 463 | $4K | |
| 80061 | Lipid panel | <1% | 256 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,052 | $3K |
| 92083 | <1% | 43 | $2K | |
| 82607 | <1% | 112 | $1K | |
| 82746 | <1% | 112 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 52 | $907.60 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 91 | $851.80 |
| 73630 | <1% | 28 | $757.19 | |
| 72202 | <1% | 24 | $746.90 | |
| 84550 | <1% | 181 | $716.36 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 28 | $712.26 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 460 | $673.30 |
| 82570 | <1% | 80 | $360.33 | |
| 82550 | <1% | 49 | $272.13 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 463 | $131.32 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARSON, CRAIG (PRESIDENT)